ZIVO Bioscience, Inc.

ZIVO

US98978N3098

Food Processing

Market Closed - OTC Markets Other stock markets 02:43:42 2024-05-31 pm EDT			5-day change	1st Jan Change
7.96 ^USD	-0.25%		-0.25%	+563.33%

May. 13	ZIVO Bioscience, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Mar. 15	ZIVO Bioscience, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

ZIVO Bioscience, Inc. Announces Executive Changes

January 10, 2022 at 05:00 pm EST

ZIVO Bioscience, Inc. announced that Chairman of the Board John B. Payne has been named Chief Executive Officer of the Company. Mr. Payne succeeds Andrew A. Dahl. Mr. Payne has served as a member of the ZIVO Board of Directors since July 2013 and as Chairman since December 2019.

Mr. Payne was the founder of Compassion-First Pet Hospitals and served as President and CEO from 2014 until 2020. Mr. Payne currently serves as Chairman of the Board for American Humane and as Vice Chairman of the Board of Regents at Ross University School of Medicine and School of Veterinary Medicine.

Latest news about ZIVO Bioscience, Inc.

ZIVO Bioscience, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 13	CI
ZIVO Bioscience, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 15	CI
ZIVO Bioscience, Inc. Reports Additional Findings from Positive 42-Day Coccidiosis Challenge Study	Feb. 07	CI
Zivo Bioscience Reports Positive Efficacy Results from 42-Day Validation Study with Non-Antibiotic Immune-Modulating Product for the Prevention and Treatment of Coccidiosis in Broiler Chickens	Jan. 23	CI
ZIVO Bioscience, Inc. announced that it has received $0.531142 million in funding	Jan. 15	CI
ZIVO Bioscience, Inc. announced that it expects to receive $0.531142 million in funding	Jan. 03	CI
ZIVO Bioscience, Inc. announced that it has received $0.308936 million in funding	Dec. 26	CI
ZIVO Bioscience, Inc. announced that it expects to receive $0.308936 million in funding	Dec. 11	CI
ZIVO Bioscience, Inc. announced that it has received $0.2 million in funding	Dec. 04	CI
ZIVO Bioscience, Inc.(NasdaqCM:ZIVO) dropped from S&P TMI Index	Nov. 29	CI
ZIVO Bioscience, Inc.(OTCPK:ZIVO) dropped from NASDAQ Composite Index	Nov. 24	CI
ZIVO Bioscience, Inc. announced that it expects to receive $0.15 million in funding	Nov. 15	CI
ZIVO Bioscience, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Zivo Bioscience Insider Bought Shares Worth $199,600, According to a Recent SEC Filing	23-10-30	MT
Zivo Says Trial Results Confirm Efficacy of Non-Antibiotic Product Candidate for Treating Coccidiosis in Broiler Chickens	23-09-19	MT
Trial Results Confirm Efficacy of ZIVO Bioscience?s Non-Antibiotic Product Candidate for the Prevention and Treatment of Coccidiosis in Broiler Chickens	23-09-19	CI
ZIVO Bioscience, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Zivo Bioscience, Inc. Commences Sales of Its Proprietary Algal Biomass as Human Food	23-07-26	CI
Zivo Biosciences to Raise $4 Million From Registered Direct Offering, Concurrent Private Placement; Shares Drop	23-06-30	MT
ZIVO Bioscience, Inc.(NasdaqCM:ZIVO) dropped from Russell 3000E Index	23-06-23	CI
ZIVO Bioscience, Inc.(NasdaqCM:ZIVO) dropped from Russell Microcap Index	23-06-23	CI
ZIVO Bioscience, Inc.(NasdaqCM:ZIVO) dropped from Russell Microcap Growth Index	23-06-23	CI
ZIVO Bioscience, Inc.(NasdaqCM:ZIVO) dropped from Russell 3000E Growth Index	23-06-23	CI
Zivo Bioscience, Inc. Announces its GRAS Designation Reaffirmed for Proprietary Algal Biomass Product as Human Food Ingredient	23-05-30	CI
ZIVO Bioscience, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-10	CI

Chart ZIVO Bioscience, Inc.

Duration

Period

More charts

Company Profile

Zivo Bioscience, Inc. is a research and development company. The Company operates in both the biotech and agtech sectors, with an intellectual property portfolio comprised of algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques and patented or patent-pending inventions for applications in human and animal health. Its product candidates are at different stages of development for different applications. It is developing a product candidate targeting poultry gut health. It is developing products for Bovine Mastitis, Canine Joint Health, Human Immune Modulation, Algal biomass for human consumption, and Biomass for supporting skin health/anti-aging. It is focused on licensing and selling natural bioactive ingredients derived from their proprietary algae cultures to animal, human and dietary supplement, and medical food manufacturers.

Sector

Food Processing

Calendar

2024-06-11 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for ZIVO Bioscience, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

7.96 USD

Average target price

12 USD

Spread / Average Target

+50.75%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Special Foods & Wellbeing Products

	1st Jan change	Capi.
ZIVO BIOSCIENCE, INC.	+563.33%	22.6M
ZHEJIANG NHU COMPANY LTD.	+11.85%	8.05B
BELLRING BRANDS, INC.	+5.29%	7.59B
CSPC INNOVATION PHARMACEUTICAL CO., LTD.	+2.63%	6.07B
THE SIMPLY GOOD FOODS COMPANY	-2.80%	3.85B
BYHEALTH CO., LTD	-11.22%	3.55B
XIAMEN KINGDOMWAY GROUP COMPANY	-7.04%	1.28B
HERBALIFE LTD.	-32.50%	1.03B
SIRIO PHARMA CO., LTD.	+12.52%	971M
JAMIESON WELLNESS INC.	-15.69%	813M

Special Foods & Wellbeing Products